Full-Time

Senior Regulatory Operations Manager

Regulatory Operations

Nurix Therapeutics

Nurix Therapeutics

201-500 employees

Drug discovery targeting ubiquitin E3 ligases

Compensation Overview

$140k - $162k/yr

+ Bonus + Equity

Daly City, CA, USA

In Person

On-site role based in Brisbane, California; no remote work.

Category
Legal & Compliance (1)
Required Skills
Veeva
Word/Pages/Docs
Google Cloud Platform
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Nurix Therapeutics

See people who can refer or advise you

Requirements
  • Bachelor's Degree in Life Sciences or relevant field
  • Minimum of 5 years’ experience working in Regulatory Affairs or Regulatory Operations. Additional experience in the biotechnology or pharmaceutical industry preferred
  • Understanding of the drug development process
  • Proficient knowledge of Veeva RIMS SCP, workflows, archival, reporting
  • Experienced publisher (DocuBridge, GlobalSubmit, VeevaVault Submission)
  • Experience successfully supporting critical deliverables while maintaining agreed timelines
  • Demonstrated ability to work effectively with cross-functional teams or collaborative environments.
  • Basic knowledge of 21 CFR and FDA, ICH, GCP, GMP, eCTD, and global guidelines.
  • Previous experience with building electronic submissions in compliance with Health Authority requirements is a plus
  • Previous experience with maintaining in-house repository for archiving regulatory submissions and Health Authority correspondence in 21 CFR Part 11 compliant system (e.g., Veeva) is a plus
  • Able to take ownership of a given assignment, proactively consulting other project team members and other department representatives for information or guidance, as necessary
  • Superior communication skills: oral, written, with proven negotiation skills, and strong time-management
  • Excellent Computer Skills MS Word, Excel, Power Point, Smartsheet and document management software/system, templates
  • Nurix is located in Brisbane, CA - this is an onsite position.
Responsibilities
  • Under the strategic direction of the SVP of Regulatory Affairs and the Director of Regulatory Affairs PM and Operations, the candidate will support the planning, coordination, tracking and execution of submissions and responses to global regulatory authorities
  • Assist Regulatory team, project teams and Clinical Research Organization (CRO) counterparts in the implementation of regulatory plans, timely delivery, and submission of regulatory documentation
  • Preparation of Regulatory submission documentation (e.g Forms, Cover Letter) as requested
  • Support team with formatting, QC and publishing of submission documents and packages
  • Manage and support Veeva RIMS processes such as HAI, SCP and Archiving
  • Manage authoring and review workflow in Veeva RIMS according to defined timelines
  • Coordinate with regulatory colleagues and cross-functional departments to prepare, compile, review, and submit documents or information necessary to health authorities in accordance with regulations, guidelines or queries IN Veeva RIMS using SCP
  • Maintain archival copies of health authority submissions (e.g., IND, CTA, NDA, and MAA), correspondence and a record of health authority obligations, and commitments
  • Maintain current knowledge of applicable US and global regulations, guidance, and standards for drug development and product registration. Participate in Regulatory Intelligence activities to help inform team members of new applicable guidelines and conduct training sessions on new guidelines/regulations if necessary
  • Participate in kick-off and project-based meetings related to regulatory submissions, strategy, and comment resolution. Be a reliable resource for information following such meetings
  • Follow general instructions from Regulatory management or company leadership for assigned projects while independently planning daily work tasks to complete projects on time. Seek guidance on project/task priorities as needed
  • Communicate important project decisions or challenges to Regulatory leadership
  • Create or contribute to Standard Operating Procedures (SOP), checklists and training Materials for Regulatory department activities
  • Support contracts and Purchase order for the Regulatory Affairs department

Nurix Therapeutics develops drugs that use the body's own protein-degradation system to treat diseases. Its core approach is to control ubiquitin E3 ligases, enzymes that tag unwanted proteins for breakdown in cells. By modulating these ligases, Nurix aims to create therapeutics, especially small-molecule immuno-oncology agents, that can selectively remove disease-related proteins in cancer and other serious conditions. The company operates by discovering and developing drug candidates and earning revenue through partnerships, licensing, and potential future sales of its medicines. Unlike many biotech firms that target single proteins, Nurix focuses on the protein-degradation pathway to influence multiple disease processes through carefully designed molecules. The goal is to bring new cancer treatments and other therapies to patients by advancing its degrader-based drugs through research, collaboration, and development toward commercial use.

Company Size

201-500

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2012

Get referred to Nurix Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Roche provides $700 million upfront and up to $2.3 billion in milestones for bexobrutideg.[2]
  • Roche funds 60% of development costs, reducing Nurix’s capital burden on the lead program.[2]
  • Phase 3 CLL initiation in mid-2026 creates a near-term catalyst for valuation re-rating.[1]

What critics are saying

  • NX-5948 has no Phase 3 efficacy or safety validation yet.[1]
  • Roche controls ex-U.S. commercialization, limiting Nurix’s global commercial leverage.[2]
  • Nurix remains heavily dependent on partner-backed programs for funding and late-stage validation.[3]

What makes Nurix Therapeutics unique

  • Nurix specializes in targeted protein degradation through E3 ligase biology and BTK degraders.[2][3]
  • Bexobrutideg/NX-5948 is the lead BTK degrader, now advancing toward Phase 3 CLL.[1]
  • The pipeline spans oncology, immunology, and neurology, widening the platform beyond one indication.[1][2]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-3%

2 year growth

-2%
Nurix Therapeutics
May 12th, 2026
Press releases.

Press releases. Nurix Therapeutics announces bexobrutideg oral presentation at the 2026 European Hematology Association Congress. May 12, 2026 BRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) - Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that an abstract highlighting updated efficacy and safety data from the ongoing Phase 1a/b trial of BTK degrader bexobrutideg (NX-5948) in patients with chronic lymphocytic leukemia (CLL) across lines of therapy has been accepted for oral presentation at the 31st Congress of the European Hematology Association (EHA2026), taking place June 11-14, 2026, in Stockholm, Sweden. Oral Presentation Details: Title: Updated efficacy and safety data from an ongoing phase 1a/b trial of the BTK degrader bexobrutideg (NX-5948) in patients with CLL across lines of therapy Presenter: Tahla Munir, MBChB, Ph.D. Session title: s449 Novel therapies in relapsed/refractory CLL Session date and time: June 14, 2026, 11:00 - 12:15 CEST Session Room: A10-11 Hall Abstract ID: S150 About Bexobrutideg (NX-5948) Bexobrutideg is an investigational, orally bioavailable, brain penetrant, highly selective small molecule degrader of Bruton's tyrosine kinase (BTK) currently being evaluated in the DAYBreak CLL-201 clinical trial (NCT07221500), a pivotal single-arm Phase 2 study of bexobrutideg in patients with relapsed or refractory CLL. Nurix also continues enrollment in the NX-5948-301 Phase 1a/1b clinical trial (NCT05131022) of bexobrutideg in patients with relapsed or refractory B cell malignancies. Additional information on the ongoing clinical trials can be accessed at clinicaltrials.gov. About Nurix Therapeutics, Inc. Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix's wholly owned, clinical stage pipeline includes degraders of Bruton's tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix's partnered drug discovery pipeline consists of a preclinical stage degrader of STAT6, SAR448272/NX-3911, in collaboration with Sanofi, a clinical stage degrader of IRAK4, GS6791, in collaboration with Gilead, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class, and coupled with unparalleled ligase expertise, Nurix's dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine's next chapter with a new script to outmatch disease. Nurix is headquartered in Brisbane, California. For additional information visit http://www.nurixtx.com.